1995
Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience
Wong S, Baim D, Schatz R, Teirstein P, King S, Curry R, Heuser R, Ellis S, Cleman M, Overlie P, Hirshfeld J, Walker C, Litvack F, Fish D, Brinker J, Buchbinder M, Goldberg S, Chuang Y, Leon M, Group P. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience. Journal Of The American College Of Cardiology 1995, 26: 704-712. PMID: 7642863, DOI: 10.1016/0735-1097(95)00217-r.Peer-Reviewed Original ResearchConceptsSaphenous vein graft lesionsVein graft lesionsGraft lesionsStent implantationDiameter stenosisStent placementActuarial event-free survivalFavorable late clinical outcomeNative coronary artery diseaseSaphenous vein graft angioplastySaphenous vein graft diseaseImproved long-term outcomesMultivariate logistic regression analysisFrequent periprocedural complicationsLate clinical outcomesStandard balloon angioplastyStent placement resultsVein graft angioplastyEvent-free survivalProcedural success rateOverall restenosis rateVein graft diseaseCoronary artery diseaseReference vessel sizeLong-term outcomes
1990
Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol®11Fluosol® (20% Intravascular Perfluorochemical Emulsion) is a registered trademark of The Green Cross Corporation, Osaka, Japan.
Kent K, Cleman M, Cowley M, Forman M, Jaffe C, Kaplan M, King S, Krucoff M, Lassar T, McAuley B, Smith R, Wisdom C, Wohlgelernter D. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol®11Fluosol® (20% Intravascular Perfluorochemical Emulsion) is a registered trademark of The Green Cross Corporation, Osaka, Japan. The American Journal Of Cardiology 1990, 66: 279-284. PMID: 2195864, DOI: 10.1016/0002-9149(90)90836-p.Peer-Reviewed Original ResearchConceptsOxygen-carrying perfluorochemical emulsionFluosol perfusionAngioplasty patientsMyocardial ischemiaPerfluorochemical emulsionBaseline levelsGlobal left ventricular ejection fractionLeft ventricular ejection fractionPercutaneous transluminal coronary angioplastyRegional wall dysfunctionSevere anginal painTransluminal coronary angioplastyVentricular ejection fractionST-segment changesAnginal painGreen Cross CorporationCoronary angioplastyEjection fractionMulticenter trialRoutine angioplastyVentricular functionBalloon occlusionBalloon deflationPatient populationBalloon inflation
1988
Percutaneous Transluminal Coronary Angioplasty During Acute Myocardial Infarction
Remetz M, Cleman M. Percutaneous Transluminal Coronary Angioplasty During Acute Myocardial Infarction. Cardiology Clinics 1988, 6: 139-152. PMID: 2971441, DOI: 10.1016/s0733-8651(18)30507-1.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonClinical Trials as TopicCombined Modality TherapyCoronary CirculationFibrinolytic AgentsHumansMyocardial InfarctionConceptsSystemic thrombolytic therapyThrombolytic therapyVentricular functionAcute MISymptom onsetAcute PTCABlood flowPercutaneous transluminal coronary angioplastyInitial thrombolytic therapyRecent cerebrovascular eventsIntravenous thrombolytic therapyCent of patientsInfarct-related arteryPost-infarction anginaRegional left ventricular functionImproved ventricular functionTransluminal coronary angioplastyLeft ventricular functionAcute myocardial infarctionIntravenous r-tPASecond generation thrombolytic agentUse of PTCAAcute angioplastyIntracoronary streptokinaseProvokable ischemia